Friday, July 31, 2026

Celltrion sees prescription growth for key products in Europe, raises expectations for high-margin new drugs

Celltrion's cancer and autoimmune disease treatments are achieving stable growth in Europe, expanding their market influence.

Blood Test Alone May Predict Chemotherapy Response and Prognosis in Lymphoma Patients

South Korean researchers discover a mechanism reducing rituximab's effectiveness in DLBCL and propose a predictive blood biomarker.

Tumors Shrinking, Hopes Rising: Voronoi’s VRN11 Shows Over 40% Tumor Reduction in Early Lung Cancer Trial

Voronoi's VRN11 shows promising anti-cancer efficacy in early trials, reducing tumors in resistant lung cancer patients without major side effects.

Tag: pharmacokinetics

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Unlocking Cancer Treatment: Samsung Bioepis Achieves Keytruda Biosimilar Equivalence in Global Trials

Samsung Bioepis' biosimilar SB27 shows equivalence to Keytruda in key clinical trials, enhancing access to cancer immunotherapy.

IVL3021 vs Wegovy: The Future of Long-Acting Obesity Treatments Revealed

Inventage Lab's IVL3021 shows promising long-term obesity treatment results, outperforming competitors with effective weight maintenance strategies.

Daewoong’s Enavogliflozin Shows Consistent Glucose-Lowering Effects Across Korean and Chinese Patients

Daewoong's diabetes drug Enblo shows similar effects in Korean and Chinese patients, supporting its global expansion and future approvals.

A Long-Acting Oral Drug? Yuhan’s Latest Trial Update Is Turning Heads

Yuhan Corp's YH35995 shows promising results for Gaucher disease in Phase 1 trial, demonstrating long-lasting efficacy and BBB penetration.

SJN314: The Promising New Immunotherapy for Chronic Inflammatory Diseases in Asia

Samjin Pharmaceutical submits phase 1 trial plan for SJN314, targeting immune diseases, aiming for global partnerships in early clinical phases.

Is RPG-102 the Future of Obesity Treatment? Discover the Breakthrough Oral Solution!

ProGen and Rani Therapeutics initiate a Phase 1 trial for RPG-102, an oral obesity treatment, aiming for effective weight loss with weekly dosing.

Celltrion’s ‘Psoriasis’ Biosimilar Poised to Challenge Big Pharma with Phase 1 Data

The EADV conference in Paris showcased Celltrion's biosimilar CT-P55, confirming its equivalence to Cosentyx in safety and pharmacokinetics.

Tumors Shrinking, Hopes Rising: Voronoi’s VRN11 Shows Over 40% Tumor Reduction in Early Lung Cancer Trial

Voronoi's VRN11 shows promising anti-cancer efficacy in early trials, reducing tumors in resistant lung cancer patients without major side effects.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.